Decisions about Voriconazole versus Liposomal Amphotericin B
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Voriconazole is superior to liposomal amphotericin B in the prevention of breakthrough fungal infections in high-risk patients.
“voriconazole has been shown to be superior to liposomal amphotericin B in the prevention of breakthrough fungal infections in high-risk patients (A-I).”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [153]
Voriconazole is superior to liposomal amphotericin B in the prevention of breakthrough fungal infections in high-risk patients.
“voriconazole has been shown to be superior to liposomal amphotericin B in the prevention of breakthrough fungal infections in high-risk patients (A-I).”
From Guidelines for Treatment of Candidiasis (2004) · cites this paper as [154]
Cites
Walsh, T. J., Pappas, P., Winston, D. J., Lazarus, H. M., Petersen, F., Raffalli, J., Yanovich, S., Stiff, P., Greenberg, R., Donowitz, G., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460403 · Cited by 979 · see citing works
Self-citationEmpirical Antifungal Therapy — New Options, New Tradeoffs
Marr, K. A. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460410 · Cited by 71 · see citing works
Voriconazole versus Liposomal Amphotericin B in Patients with Neutropenia and Persistent Fever
Powers, J. H., Dixon, C. A., & Goldberger, M. J. (2002) · New England Journal of Medicine · doi:10.1056/nejm200201243460414 · Cited by 61 · see citing works
McMillan, D. A., Lin, C. Y.-C., Aronin, S. I., et al. (2002) · Clinical Infectious Diseases · doi:10.1086/339803 · Cited by 11 · see citing works
Flagged first, then by citations
Cited by
Sorted by citations
Guidelines for Treatment of Candidiasis
Pappas, P. G., Rex, J. H., Sobel, J. D., Filler, S. G., Dismukes, W. E., Walsh, T. J., & Edwards, J. E. (2004) · Clinical Infectious Diseases · doi:10.1086/380796 · Cited by 1,440 · see citing works
Self-citation
- Authors
- Walsh, T. J., Lee, J. Y., & Dismukes, W. E.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2002-05-09
- Volume
- 346
- Issue
- 19
- Pages
- 1499-1499
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2206163629
- Cited by
- 14
- References
- 4
- Citations by year
- 2014: 1
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Infectious Diseases › Antifungal resistance and susceptibility
- Health Sciences › Medicine › Epidemiology › Fungal Infections and Studies
- Health Sciences › Medicine › Ophthalmology › Ocular Infections and Treatments
- Keywords
- voriconazole, liposomal amphotericin B, antifungal therapy, treatment decision-making, invasive fungal infections
- MeSH terms
- Amphotericin B, Antifungal Agents, Clinical Protocols, Data Interpretation, Statistical, Fever, Humans, Mycoses, Neutropenia, Pyrimidines, Research Design, Triazoles, Voriconazole
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
